Sign In
Buy BPTH
$0.0300
+0.0066 (+28.21%)
At Close: Jun 03, 2026
Bio-Path Holdings Provides 2024 Clinical and Operational Update
07:00am, Tuesday, 02'nd Apr 2024
HOUSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develo
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q4 23
04:43pm, Wednesday, 27'th Mar 2024
Dallas, Texas--(Newsfile Corp. - March 27, 2024) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) for Q4 2023. To view th
Bio-Path Holdings Inc. (BPTH) Q4 2023 Earnings Call Transcript
10:28am, Friday, 08'th Mar 2024
Bio-Path Holdings Inc. (NASDAQ:BPTH ) Q4 2023 Results Conference Call March 8, 2024 8:30 AM ET Company Participants Will O'Connor - Stern Investor Relations Peter Nielsen - CEO and CFO Anthony Price -
Bio-Path Holdings Reports Full Year 2023 Financial Results
07:00am, Friday, 08'th Mar 2024
HOUSTON, March 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develo
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024
07:00am, Friday, 01'st Mar 2024
HOUSTON, March 01, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a p
Bio-Path Holdings Announces 1-for-20 Reverse Stock Split
07:00am, Wednesday, 21'st Feb 2024
Shares of Common Stock Will Begin Trading on a Split-Adjusted Basis on February 23, 2024 Shares of Common Stock Will Begin Trading on a Split-Adjusted Basis on February 23, 2024
Targeting Bcl-2 Protein Offers Potential Treatment for Patients Who Have Failed or Relapsed from Venetoclax-Based Frontline Therapy Targeting Bcl-2 Protein Offers Potential Treatment for Patients Who
BP1002 Offers Unique Opportunity for Venetoclax-Resistant Patients by Utilizing RNAi to Limit Cells' Ability to Produce Bcl-2 Protein BP1002 Offers Unique Opportunity for Venetoclax-Resistant Patients
Bio-Path Holdings, Inc. (BPTH) Q3 2023 Earnings Call Transcript
05:28pm, Wednesday, 15'th Nov 2023
Bio-Path Holdings, Inc. (NASDAQ:BPTH ) Q3 2023 Earnings Call Transcript November 15, 2023 8:30 AM ET Company Participants Will O'Connor - IR, Stern IR Peter Nielsen - President and CEO Anthony Price -
Bio-Path Holdings Reports Third Quarter 2023 Financial Results
07:00am, Wednesday, 15'th Nov 2023
HOUSTON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop
Bio-Path Holdings to Announce Third Quarter 2023 Financial Results on November 15, 2023
07:00am, Wednesday, 08'th Nov 2023
HOUSTON, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a po
Bio-Path Holdings to Present at H.C. Wainwright 25th Annual Global Investment Conference
04:01pm, Friday, 08'th Sep 2023
HOUSTON, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develo
Bio-Path Holdings, Inc. (BPTH) Q2 2023 Earnings Call Transcript
01:44pm, Tuesday, 15'th Aug 2023
Bio-Path Holdings, Inc. (NASDAQ:BPTH ) Q2 2023 Results Conference Call August 15, 2023 8:30 AM ET Company Participants Will O'Connor - Investor Relations, Stern IR Peter Nielsen - President and Chief
Bio-Path Holdings to Announce Second Quarter 2023 Financial Results on August 15, 2023
07:00am, Tuesday, 08'th Aug 2023
HOUSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a
Why Is Bio-Path (BPTH) Stock Down 12% Today?
09:17am, Monday, 26'th Jun 2023
Bio-Path (NASDAQ: BPTH ) stock is sliding lower on Monday after the company announced a proposed public share offering. Bio-Path has yet to reveal the major details of its planned public offering.
